PA 83 FhCMB

Drug Profile

PA 83 FhCMB

Alternative Names: PA83 FhCMB; Plant derived recombinant protective antigen anthrax vaccine; rPA anthrax vaccine

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator iBio Inc
  • Developer Fraunhofer USA Center for Molecular Biotechnology
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anthrax

Most Recent Events

  • 30 Nov 2015 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in China
  • 01 Aug 2014 Phase-I clinical trials in Anthrax (Prevention) in USA (Parenteral) (NCT02239172)
  • 30 Sep 2013 Preclinical development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top